Table 1.
Patient Characteristics of R/R DLBCL Evaluated in Model
| Characteristics | SEAL All | SEAL* (R/R- IPI Model Subset) |
LYFO Cohort (Validation) |
MER Cohort (Validation) |
|---|---|---|---|---|
| (N=1234) | (N=1036) | (N=592) | (N=305) | |
| Age at Diagnosis (Years) | ||||
| Mean (SD) | 62.6 (12.8) | 64.3 (9.2) | 65.5 (9.1) | 62.1 (9.7) |
| Median | 66 | 66 | 66 | 62 |
| IQR | 56.0, 71.8 | 59.0, 71.1 | 60.0, 72.0 | 56.0, 70.0 |
| Range | 19.0, 87.5 | 39.0, 79.2 | 41.0, 80.0 | 39.0, 79.0 |
| Age at Progression (Years) | ||||
| Mean (SD) | 64.1 (13.2) | 65.5 (9.4) | 66.9 (9.2) | 63.2 (9.8) |
| Median | 67.5 | 67.5 | 68 | 63.2 |
| IQR | 57.4, 73.5 | 59.7, 72.8 | 61.0, 74.0 | 57.4, 71.4 |
| Range | 19.2, 92.0 | 40.1, 79.9 | 41.0, 85.0 | 40.1, 79.8 |
| Sex, n (%) | ||||
| Male | 675 (54.7%) | 572 (55.2%) | 360 (60.8%) | 116 (38.0%) |
| Female | 559 (45.3%) | 464 (44.8%) | 232 (39.2%) | 189 (62.0%) |
| Time to Progression (Months) | ||||
| Mean (SD) | 18.4 (19.5) | 15.3 (12.7) | 16.9 (19.8) | 13.1 (11.9) |
| Median | 11.3 | 10.9 | 9.7 | 8.1 |
| IQR | 6.3, 22.6 | 6.3, 20.0 | 5.8, 18.1 | 5.1, 18.3 |
| Range | 0.1, 167.0 | 0.1, 59.4 | 1.3, 130.7 | 0.5, 56.6 |
| Ann Arbor Stage (Diagnosis) | ||||
| I & II | 284 (23.0%) | 215 (20.8%) | 123 (20.8%) | 63 (20.7%) |
| III & IV | 949 (77.0%) | 820 (79.2%) | 467 (79.2%) | 242 (79.3%) |
| Missing | 1 | 1 | 2 | |
| ECOG Performance Status (Diagnosis) | ||||
| 0-1 | 998 (80.9%) | 834 (80.5%) | 450 (76.7%) | 236 (77.4%) |
| 2-4 | 236 (19.1%) | 202 (19.5%) | 137 (23.3%) | 69 (22.6%) |
| Extranodal Sites (Diagnosis) | ||||
| <= 1 | 660 (62.3%) | 538 (60.7%) | 378 (63.9%) | 236 (77.4%) |
| > 1 | 400 (37.7%) | 348 (39.3%) | 214 (36.1%) | 69 (22.6%) |
| Missing | 174 | 150 | 0 | |
| LDH Status (Diagnosis) | ||||
| Not Elevated | 384 (31.6%) | 312 (30.5%) | 152 (26.5%) | 72 (23.6%) |
| Elevated | 833 (68.4%) | 712 (69.5%) | 421 (73.5%) | 233 (76.4%) |
| Missing | 17 | 12 | 19 | |
| IPI Score (Diagnosis) | ||||
| 0-1 | 245 (19.9%) | 177 (17.1%) | 79 (13.9%) | 54 (17.7%) |
| 2 | 378 (30.6%) | 318 (30.7%) | 131 (23.1%) | 100 (32.8%) |
| 3 | 393 (31.8%) | 338 (32.6%) | 173 (30.5%) | 102 (33.4%) |
| 4-5 | 218 (17.7%) | 203 (19.6%) | 184 (32.5%) | 49 (16.1%) |
| Induction Treatment (Diagnosis) | ||||
| R-CHOP21 | 599 (48.5%) | 491 (47.4%) | 185 (31.3%) | 223 (73.1%) |
| Other† | 635 (51.5%) | 545 (52.6%) | 407 (68.8%) | 82 (26.9%) |
†
Not R-CHOP21
*
SEAL R/R IPI final modelling dataset restricted to age 40-80 and TTP between 0 and 60 month
Abbreviations: IC, Immunochemotherapy; TTP, Time to Progression; R/R, Relapse or Refractory; LDH, Lactate Dehydrogenase; IPI, International Prognostic Index; SEAL, Surrogate Endpoint for Aggressive Lymphoma; LYFO, Danish National Lymphoma Register; MER, Iowa/Mayo SPORE Molecular Epidemiology Resource.